Biotech and Pharma Industry News | BioPharma Dive
Jan 14, 2025 · BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Biotech startups are built on venture capital. Track funding rounds ...
Nov 21, 2024 · Drug development is an expensive, risky endeavor. Biotechnology companies just starting out are many years away from seeing profits, if ever. So more often than not, a startup’s success turning science into medicines can come down to how much money it raises.
Novo Holdings’ purchase of Catalent set to close after regulators ...
Dec 16, 2024 · Dive Brief: Novo Holdings can complete its $16.5 billion acquisition of contract drug manufacturer Catalent after antitrust regulators in the U.S. declined to challenge the deal before the expiry of a deadline, the companies said Saturday.
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
Nov 22, 2024 · Notably, the drug is approved to prevent hospitalization or death resulting from heart complications of transthyretin amyloidosis with cardiomyopathy. Investors had been skeptical BridgeBio would earn such a distinction from regulators, leading to doubts about Attruby’s commercial prospects.. BridgeBio priced Attruby at just under $19,000 for a 28-day supply, translating to an annual list ...
NewAmsterdam drug shows ‘unexpected’ signs of protecting the …
Dec 10, 2024 · Obicetrapib’s safety profile, including its potential impact on blood pressure — a concern for drugs of its kind, known as CETP inhibitors — were also comparable to a placebo.A higher percentage of patients in the placebo arm dropped out of the trial due to treatment-related side effects, NewAmsterdam said.
The top biopharma conferences in 2025 | BioPharma Dive
Oct 1, 2024 · American Association of Cancer Research Annual Meeting. April 25 - 30, 2025 Chicago. While the American Society of Clinical Oncology’s meeting often gets billed as the field’s largest conference, AACR has become an equally major gathering for cancer research, particularly earlier-stage findings on new drug mechanisms of action or treatment modalities.
With new data, Lilly sets pace for next wave of breast cancer drugs
Dec 11, 2024 · An experimental breast cancer drug developed by Eli Lilly met its main goal in a Phase 3 study, helping people with a form of HER2-negative, ER-positive disease stay alive and progression free for longer than standard hormone-suppressing therapies, according to data disclosed Wednesday.. When combined with Lilly’s approved medicine Verezenio, the experimental drug, called imlunestrant, also ...
Regeneron says study data support big bet on new blood thinners
Dec 19, 2024 · Dive Brief: Regeneron Pharmaceuticals intends to advance two blood-thinning drugs into Phase 3 testing next year after mid-stage study results showed they matched or surpassed marketed medicines at preventing blood clots following knee replacement surgery.; Regeneron’s drugs block a clotting protein, Factor XI, that’s been targeted by multiple pharmaceutical companies, some of which have ...
The biopharma industry outlook on 2024: Guarded optimism for a …
Jan 16, 2024 · Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024.. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a more strident Federal Trade Commission, further weighed on the sector.. There are now some signs of a turnaround, from a rebounding ...
Merck calls quits on two immunotherapies for cancer
Merck & Co. on Dec. 16, 2024, cancelled work on combination therapies with its cancer drug Keytruda. Sundry Photography via Getty Images